Drugs are applied to the skin for the treatment of a wide range of conditions including both local (inflammation, pain, eczema, psoriasis) and systemic (angina, nicotine withdrawl, hormone replacement therapy) therapies. Unwanted skin absorption also occurs following exposure to environmental and occupational chemicals, including those applied deliberately to the skin such as insectisides, sunscreens and cosmetics. This study seeks to examine the relationship between the chemical structure of ag ....Drugs are applied to the skin for the treatment of a wide range of conditions including both local (inflammation, pain, eczema, psoriasis) and systemic (angina, nicotine withdrawl, hormone replacement therapy) therapies. Unwanted skin absorption also occurs following exposure to environmental and occupational chemicals, including those applied deliberately to the skin such as insectisides, sunscreens and cosmetics. This study seeks to examine the relationship between the chemical structure of agents, the types of formulations in which they are applied and their penetration into the various layers of the skin and underlying tissues. We intend to further our research into important areas relating to the ability to predict the likely behaviour of a solute which comes into contact with the skin from the aspect of optimising both topical drug delivery systems and risk assessment procedures. We will also be examining techniques of facilitating drug transport through the skin using (i) the knowledge gained of the mechanisms by which vehicles act on the skin, (ii) the synthesis of ester and amide lipophilic prodrugs and (iii) physical techniques such as iontophoresis, whereby small electrical currents are applied to charged drug species on the outside of the skin.Read moreRead less
Drugs are applied to the skin for the treatment of a wide range of conditions, including both local (eg. inflammation, muscle pain, eczema, psoriasis and other dermatological conditions) and systemic (eg. angina, hormone replacement, nicotine withdrawal) therapies. Advances in molecular biology technology has also led to the development of a range of large molecular weight peptide and protein based therapeutic agents for which transdermal delivery offers the most cost-effective and practical sol ....Drugs are applied to the skin for the treatment of a wide range of conditions, including both local (eg. inflammation, muscle pain, eczema, psoriasis and other dermatological conditions) and systemic (eg. angina, hormone replacement, nicotine withdrawal) therapies. Advances in molecular biology technology has also led to the development of a range of large molecular weight peptide and protein based therapeutic agents for which transdermal delivery offers the most cost-effective and practical solution if appropriate delivery systems can be identified. In addition, unwanted skin absorption also occurs following exposure to environmental occupational chemicals, and those applied deliberately to the skin such as insecticides, sunscreens and cosmetics. This study continues our work in seeking to define the relationship between the chemical structure of agents, the types of formulations and solvents in which they are applied or come into contact with the skin and their penetration, distribution and retention in the various layers of the skin and underlying tissues. Of great significance to both the pharmaceutical industry and risk assessment regulatory bodies will be the further development of our work into important areas relating to the ability to predict the likely behaviour of a solute following contact with the skin from the aspect of both optimising drug delivery systems and the accuracy of risk assessment procedures. We will also be continuing our work examining techniques to facilitate drug transport through the skin using physical techniques such as iontophoresis and the design of formulations to specifically target larger pores in the skin such as hair follicles as a means of improving delivery rates and increasing the range of solutes, particularly those of large molecular weight, likely to be considered as potential drug candidates.Read moreRead less
A Biomimetic Prodrug Platform To Enable Oral Bioavailability And Target Lymphatic Disease
Funder
National Health and Medical Research Council
Funding Amount
$408,768.00
Summary
This project will allow the advance of a unique translational technology platform that provides novel drug delivery solutions. The project aims to establish the potential for a drug delivery strategy to increase the efficacy, reduce the toxicity, and transform the impact of drug therapies for a variety of conditions, including pain, hormone dysregulation, and metabolic syndrome.
Predicting The Individual Risk Of Prostate Cancer In Australian Men
Funder
National Health and Medical Research Council
Funding Amount
$348,656.00
Summary
Prostate cancer is a major cause of disability and death in Australian men. A number of factors, particularly age and family history, influence the risk of prostate cancer but, in contrast to breast cancer, we don't know what is the risk of developing prostate cancer over a period of time for a man with a specific set of risk factors. In fact, while a number of statistical models have been developed that use a woman's risk factor profile to estimate her risk of breast cancer, none is currently a ....Prostate cancer is a major cause of disability and death in Australian men. A number of factors, particularly age and family history, influence the risk of prostate cancer but, in contrast to breast cancer, we don't know what is the risk of developing prostate cancer over a period of time for a man with a specific set of risk factors. In fact, while a number of statistical models have been developed that use a woman's risk factor profile to estimate her risk of breast cancer, none is currently available for prostate cancer. We will apply standard statistical methods to existing data from the Australian Risk Factors for Prostate Cancer study and from the Australian Institute of Health and Welfare to develop a prostate cancer risk prediction model. We will test how factor like age, detailed family history, diet, baldness status and possibly previous PSA tests and prostate biopsies predict the risk. After developing the model, we will test the accuracy of the predictions in three ways. First, using existing data from the Australian Prostate Cancer Family Study, we will see whether the number of cases in a group of men is close to the number predicted by the model (calibration). Second, to test whether the model discriminate well men who develop prostate cancer from those who do not, we will collect family trees in a sample from the Melbourne Collaborative Cohort Study. We will use these data also to estimate the optimal cut point: men above this level of risk will be considered at high risk. Third, we will apply the model to existing data from the Dutch Prostate Cancer Family Study (DPCFS) to test whether the optimal cut point identify high-risk men and to validate the model in a non-Australian population. Finally, we will prepare a computer package that health professionals will use as decision-making tool in different scenarios including individual cancer risk assessment, design of prevention trials and targeting prevention programs to high-risk men.Read moreRead less
Integrating Drug Delivery Principles Into Drug Design To Transform The Treatment Of Immune Disease
Funder
National Health and Medical Research Council
Funding Amount
$552,635.00
Summary
Immune system disorders (e.g. rheumatoid arthritis, transplant rejection, Crohn’s disease, multiple sclerosis) are often treated with immunosuppresant drugs. However, immunosuppressant drugs can cause significant toxicity and can lack efficacy. This proposal will show how the design of drugs used to treat immune disorders can be changed to allow drugs to be delivered specifically to their site of action (immune cells) thereby enhancing activity and reducing toxicity.
Intelligent Total Body Scanner For Early Detection Of Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$499,963.00
Summary
Melanoma is the 4th most common cancer in Australia; the main screening tool is a time-consuming total body examination with a hand-held dermoscope. This project aims to develop a total body scanner using fast-refocusing lenses to take total body dermoscopy images of all skin lesions in approximately 6 minutes, integrated with a computer aided diagnostic tool providing a risk score for each lesion incorporating medical history, genotypic and phenotypic risk markers.